Molecular Switch Targeting Therapies Market, By Application Area (Management of Treatment-Related Toxicity, Regulation of Gene Expression and Others), By Target Therapy, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV5915
|
Published Date
August 2026
|
Pages
289
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Molecular Switch Targeting Therapies Market size was valued at US$ 830.4 Million in 2025, expanding at a CAGR of 13.5% from 2026 to 2033.
Molecular switch targeting therapies are innovative medicinal products that utilize engineered switches to control therapeutic function, persistence, engagement, and safety profiles in cells after drug administration. The molecular switch market consists of switchable CAR-T constructs, drug-coupled receptors, adapters, inducible safety switches, and gene-therapy platforms. It targets a wide range of diseases, including oncology, autoimmune and inflammatory disorders, neuroscience, and certain regenerative medicine conditions.
Companies work on similar chemical switches that allow for fine-tuning of therapy potency. At the same time, the key challenges for molecular switch technologies are the consistent production of these switches and the clinical validation of their performance. In 2025, Calibr\'s therapeutic candidate CLBR001 and switch platform SWI019 entered the clinic, indicating that molecular switches are becoming therapeutics themselves. Thus, controllability is no longer an afterthought but rather a critical component of innovative cell and gene medicines.
Molecular Switch Targeting Therapies Market- Market Dynamics
Programmable Therapeutic Control Is Expanding the Utility of Living Medicines
The ability to regulate therapeutic activity after administration is becoming increasingly important as developers seek greater control over living medicines. Existing CAR-T therapies can remain viable and therapeutically active post-transplant, which poses a problem when continued immune engagement is unwanted. Molecular switches give added control by linking activation of a switch to an administered molecule, potentially enabling clinicians to titrate therapy and avoid complete elimination of therapeutic cells. This mechanism is ideally suited to autoimmune diseases-a context wherein treatment entails more risk-benefit and longer treatment cycles than oncology Target Therapys. Calibr developed a Phase 1 program across four autoimmune indications starting in 2025, expanding on the technology into this non-oncologic field and highlighting the value proposition for programmable control to extend CAR-T Target Therapys further up the chain into an entire spectrum of diseases.
Molecular Switch Targeting Therapies Market- Geographical Insights
North America maintains a strong position in molecular-switch targeting therapies due to the presence of specialized clinical centers, cell engineering expertise, vector manufacturing infrastructure, and regulatory experience with cellular and gene therapies. At the same time, the U.S. offers opportunities for rapid development and commercialization of engineered immune-cell therapeutics. In 2025, the FDA approved Breyanzi for the treatment of marginal zone lymphoma, thereby expanding the range of lymphomas for CAR-T cell therapy. Thus, the current clinical landscape creates the basis for the development and differentiation of the next-generation switchable therapeutics. As a result, North America has become an important region for implementing programmable control approaches to cellular therapeutics.
Europe is characterized by a comprehensive regulatory framework, advanced research infrastructure, and a strong translational environment for developing molecular-switch therapeutics. The EMA\'s Advanced Therapies Committee evaluates complex cell and gene therapies, ensuring that developers generate relevant evidence on quality, manufacturing processes, biological mechanisms, and clinical indications. In 2025, 16 medicines were selected for the EMA\'s PRIME (Priority Medicines) scheme, which provides scientific and regulatory support to developers of medicines with high unmet clinical needs. Although the PRIME designation does not specifically focus on molecular-switch therapies, this scheme highlights the region\'s commitment to promoting innovative approaches to treating complex diseases. As a result, for cell-based programmable therapeutics, Europe offers a comprehensive regulatory environment combined with high-level scientific expertise.
Molecular Switch Targeting Therapies Market- Competitive Landscape:
The competition to develop cellular therapies has shifted towards the degree of control over treatment by engineers and is no longer focused on the intricacies of CAR design. Thus, firms are investing heavily in engineering cells where control over activation is achieved through adapted T-cell engagement, receivable signaling to drug-like molecules, inducible safety switches, persistence regulation, vector construction, and manufacturing processes that facilitate the preservation of critical quality attributes. Cell therapy developers with substantial clinical and regulatory expertise have advantages over those that only specialize in biotech, but the latter can profit from investing in switch technologies and partnerships. In 2025, Breyanzi extended the list of approved cancers in the US to five, indicating the value of cellular therapy producers that utilize validated CAR-T platforms. Moreover, it can be expected that cellular therapy producers will gain advantages by combining robustness in therapeutic cell types with external control mechanisms and individual adjustments.
Recent Developments:
- In April 2025, Calibr announced the initiation of a Phase I clinical trial evaluating the combination of the switchable CAR-T platform CLBR001 and SWI019 to treat four autoimmune diseases.
- In December 2025, Bristol Myers Squibb\'s Breyanzi was approved by the FDA for the treatment of patients with relapsed or refractory marginal zone lymphoma.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- aceRNA Technologies
- Autolus Therapeutics plc
- Bellicum Pharmaceuticals, Inc.
- Cellectis S.A.
- Kiromic BioPharma, Inc.
- panCELLa Inc.
- Precigen, Inc.
- Sana Biotechnology, Inc.
- Sangamo Therapeutics, Inc.
- Editas Medicine, Inc.
- Merck & Co., Inc.
- Bristol Myers Squibb
- AbbVie Inc.
- Sanofi
- Regeneron Pharmaceuticals, Inc.
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY APPLICATION AREA- MARKET ANALYSIS, 2020 - 2033
- Management of Treatment-Related Toxicity
- Regulation of Gene Expression
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY TARGET THERAPY- MARKET ANALYSIS, 2020 - 2033
- CAR-T Cell Therapy
- Gene Therapy
- Other Cell & Gene Therapies
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Biotechnology Companies
- Pharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENTS
1. Molecular Switch Targeting Therapies Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.2. Competitive Insights
3. Molecular Switch Targeting Therapies Key Market Trends
3.1. Molecular Switch Targeting Therapies Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Molecular Switch Targeting Therapies Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Molecular Switch Targeting Therapies Market Opportunities
3.4. Molecular Switch Targeting Therapies Market Future Trends
4. Molecular Switch Targeting Therapies Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Molecular Switch Targeting Therapies Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Molecular Switch Targeting Therapies Market Landscape
6.1. Molecular Switch Targeting Therapies Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Molecular Switch Targeting Therapies Market – By Application Area
7.1. Overview
7.1.1. Segment Share Analysis, By Application Area, 2025 & 2033 (%)
7.1.2. Autoimmune and Inflammatory Disorders
7.1.3. Oncology
7.1.4. Neurological Disorders
7.1.5. Others
8. Molecular Switch Targeting Therapies Market – By Target Therapy
8.1. Overview
8.1.1. Segment Share Analysis, By Target Therapy, 2025 & 2033 (%)
8.1.2. CAR-T Cell Therapy
8.1.3. Gene Therapy
8.1.4. Other Cell & Gene Therapies
9. Molecular Switch Targeting Therapies Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
9.1.2. Biotechnology Companies
9.1.3. Pharmaceutical Companies
9.1.4. Academic & Research Institutes
9.1.5. Contract Research Organizations (CROs)
9.1.6. Others
10. Molecular Switch Targeting Therapies Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
10.2.1. Overview
10.2.2. Molecular Switch Targeting Therapies Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.2.4. North America Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.2.5. North America Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.2.6. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Molecular Switch Targeting Therapies Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.6. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.9.5. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.16. Denmark
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.16.3. Denmark Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.16.4. Denmark Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.16.5. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.3.17. Rest of Europe
10.3.17.1. Overview
10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.17.3. Rest of the Europe Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.3.17.4. Rest of the Europe Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.3.17.5. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Molecular Switch Targeting Therapies Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.6. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.7.5. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.8.5. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.15. Taiwan
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.15.3. Taiwan Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.15.4. Taiwan Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.15.5. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.16. Vietnam
10.4.16.1. Overview
10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.16.3. Vietnam Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.16.4. Vietnam Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.16.5. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.4.17. Rest of APAC
10.4.17.1. Overview
10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.17.3. Rest of APAC Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.4.17.4. Rest of APAC Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.4.17.5. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Molecular Switch Targeting Therapies Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Molecular Switch Targeting Therapies Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.6. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.13. Iran
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.13.3. Iran Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.13.4. Iran Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.13.5. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.14. Qatar
10.6.14.1. Overview
10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.14.3. Qatar Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.14.4. Qatar Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.14.5. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
10.6.15. Rest of MEA
10.6.15.1. Overview
10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.15.3. Rest of MEA Market Size and Forecast, By Application Area, 2020 - 2033 (US$ Million)
10.6.15.4. Rest of MEA Market Size and Forecast, By Target Therapy, 2020 - 2033 (US$ Million)
10.6.15.5. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Molecular Switch Targeting Therapies Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. aceRNA Technologies
11.2.2. Autolus Therapeutics plc
11.2.3. Bellicum Pharmaceuticals, Inc.
11.2.4. Cellectis S.A.
11.2.5. Kiromic BioPharma, Inc.
11.2.6. panCELLa Inc.
11.2.7. Precigen, Inc.
11.2.8. Sana Biotechnology, Inc.
11.2.9. Sangamo Therapeutics, Inc.
11.2.10. Editas Medicine, Inc.
11.2.11. Merck & Co., Inc.
11.2.12. Bristol Myers Squibb
11.2.13. AbbVie Inc.
11.2.14. Sanofi
11.2.15. Regeneron Pharmaceuticals, Inc.
11.2.16. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- aceRNA Technologies
- Autolus Therapeutics plc
- Bellicum Pharmaceuticals, Inc.
- Cellectis S.A.
- Kiromic BioPharma, Inc.
- panCELLa Inc.
- Precigen, Inc.
- Sana Biotechnology, Inc.
- Sangamo Therapeutics, Inc.
- Editas Medicine, Inc.
- Merck & Co., Inc.
- Bristol Myers Squibb
- AbbVie Inc.
- Sanofi
- Regeneron Pharmaceuticals, Inc.
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY APPLICATION AREA- MARKET ANALYSIS, 2020 - 2033
- Management of Treatment-Related Toxicity
- Regulation of Gene Expression
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY TARGET THERAPY- MARKET ANALYSIS, 2020 - 2033
- CAR-T Cell Therapy
- Gene Therapy
- Other Cell & Gene Therapies
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033
- Biotechnology Companies
- Pharmaceutical Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
- Others
GLOBAL MOLECULAR SWITCH TARGETING THERAPIES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
